{
  "articles": [
    {
      "path": "about.html",
      "title": "Data analysis",
      "description": "Cochrane intervention study",
      "author": [],
      "contents": "\nThis is an website for internal use among the researchers on this study. The data are not currently provided in the codebase because I need to check with the PI about data sharing.\n\n\n\n",
      "last_modified": "2021-04-20T04:33:37+01:00"
    },
    {
      "path": "covidence.html",
      "title": "Covidence",
      "description": "For checking with Hollie and Gav.\n",
      "author": [],
      "date": "`r Sys.Date()`",
      "contents": "\n\nContents\nin this document\nnotation\nmodel definition\ndescribe the arms\nin words\ncontrast vs arm-based\ndesign matrices\nwhat should it be?\nwhat do we have?\n\n\nQA for model\nkeywords\n\nprotocol notes\nbackground\ncondition\nintervention\nhow\n\nimportant\nobjectives\n\n\n\n\n\nin this document\nmodel notes from protocol\nQA for model\nmodel definition\nThese all have different objectives, but are overlapping.\nnotation\nNetwork meta-analysis provides a means of aggregating and comparing the results of all studies examining the effect of antidepressants on an outcome of interest.\nWe now define the parameters of the model for outcome, using White et al.’s notation.\nLet \\(i = 1, \\dots, n\\) denote the study, and \\(k = 1, \\dots, K\\) denote the treatment.\nLet \\(R_i\\) be the set of treatments in study \\(i\\), which we call the study design.\nLet \\(\\theta_{ik}^a\\) be the parameter of interest in arm \\(k\\) of study \\(i\\) [@white2019].\nNow we define our problem of measuring the efficacy of antidepressants in the treatment of adults with chronic pain.\nWe have multiple outcomes. Let \\(j = 1, \\dots J\\) denote the outcome.\nLet \\(y_{jik}^a\\) denote the \\(j\\)th outcome effect for arm \\(k\\) of study \\(i\\). In a network meta-analaysis, we know it’s likely \\(R_i \\subsetneqq K\\), that is, only some of the \\(K\\) treatments are compared in each study.\nLet \\(d_{ik}^a\\) denote the contrast effect for arm \\(k\\)’s relative effect to placebo \\(k'\\) in study \\(i\\).\nmodel definition\nOur current objective is to model the primary outcomes using nma, performing the appropriate diagnostic statistical checks.\nWe need to check the inputs and the outputs are correct.\nWe can use the data to describe the arms or the contrasts.\ndescribe the arms\nWe assume\n\\[\n\\begin{cases}\ny_{jik}^a \\sim N(\\Theta_{jki}, \\Sigma_{ji})\\\\\n\\theta_{jki} \\sim N(0, \\tau^2)\n\\end{cases}\n\\] so, the model describes the measurements of each arm in a study’s effect for an outcome of interest.\nThe estimation happens on arm level, which is more precise than contrast level, but there are computational costs associated with arm-based, where contrast-based might be a solution. The output, then, is,\n\\[\nd_{ijk} := d(y_{jik}, y_{jik'}, \\sigma_{ji}^2)\n\\]\nwhere \\(d\\) is an appropriate measure of comparison, such as the \\(g\\) adjustment for standardised mean difference, between treatment \\(k\\) and overall comparator, such as placebo, \\(k'\\).\nAnd, for a contrast-based output, we would have an estimate of \\(d\\), not the components of \\(d\\),\n\\[\n\\begin{cases}\ny^c_{jikk'} \\sim N(\\delta_{jijk'}, \\sigma_{ji}^2)\\\\\n\\delta_{jik} \\sim N(0, \\tau^2)\n\\end{cases}\n\\]\n\nensure that checks are in place\nin words\nSo, we assume the observed measure \\(y^c_{jik}\\), of pain affect, \\(j\\), (ask Hollie about affect vs effect in this context), is a comparison between the \\(i\\)th study’s \\(k'\\) treatment.\nFor the pairwise meta-analyses, \\(k'\\) is fixed to placebo, however, in the nma, \\(k'\\) can be any of the set of \\(k = 1, \\dots, K\\) treatments.\nWe assume this comparison may be thought of in terms of a the \\(k\\)th treatment’s effect as compared to \\(k'\\), \\(\\delta_{ijk'}\\), \\[\ny^c_{jikk'} := \\delta_{jk'} + \\delta_{ji} + \\varepsilon_{jikk'} \n\\] - how do white et al. do the notation for nma? k vs k’?\nwhere \\[\n\\delta_{jikk'} = \\delta_{jkk'} + \\delta_{ji}\n\\] denotes the comparison of the \\(j\\)th outcome between treatments \\(k\\) and \\(k'\\) in the \\(i\\)th study, where \\(\\delta_{ji}\\) denotes the \\(i\\)th study…\ncontrast vs arm-based\ndesign matrices\nwhat should it be?\n\\[\n\\begin{array}\n\\[y^a_{j11}, y^a_{j12,}\\]\n\\end{array}\n\\]\nwhat do we have?\n\n\n\n\n# A tibble: 15 x 6\n# Groups:   .study, .trt [9]\n   .study       .trt            .r    .n .sample_size n_study_int\n   <fct>        <fct>        <int> <int>        <int>       <int>\n 1 Wang 2017    placebo         23    68           68           1\n 2 Wang 2017    duloxetine      35    83           83           1\n 3 Lipone 2020  placebo         10    22           22           1\n 4 Lipone 2020  trazodone       16    27           27           1\n 5 Lipone 2020  trazodone       14    27           27           2\n 6 Loldrup 1989 placebo         26    71           71           1\n 7 Loldrup 1989 placebo         25    66           66           2\n 8 Loldrup 1989 clomipramine    28    56           56           1\n 9 Loldrup 1989 clomipramine    29    62           62           2\n10 Loldrup 1989 mianserin       30    53           53           1\n11 Loldrup 1989 mianserin       28    64           64           2\n12 Uchio 2018   placebo         26    68           68           1\n13 Uchio 2018   placebo         27    69           69           2\n14 Uchio 2018   duloxetine      54    98           98           1\n15 Uchio 2018   duloxetine      73   114          114           2\n\nQA for model\n[ ]\nkeywords\n\n\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#ocwohzycsx .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: aliceblue;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_heading {\n  background-color: aliceblue;\n  text-align: center;\n  border-bottom-color: aliceblue;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: aliceblue;\n  border-bottom-width: 0;\n}\n\n#ocwohzycsx .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: aliceblue;\n  border-top-width: 0;\n}\n\n#ocwohzycsx .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_col_heading {\n  color: #333333;\n  background-color: aliceblue;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#ocwohzycsx .gt_column_spanner_outer {\n  color: #333333;\n  background-color: aliceblue;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#ocwohzycsx .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#ocwohzycsx .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#ocwohzycsx .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#ocwohzycsx .gt_group_heading {\n  padding: 8px;\n  color: #FFFFFF;\n  background-color: steelblue;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ocwohzycsx .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #FFFFFF;\n  background-color: steelblue;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ocwohzycsx .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#ocwohzycsx .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#ocwohzycsx .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#ocwohzycsx .gt_stub {\n  color: #333333;\n  background-color: aliceblue;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#ocwohzycsx .gt_summary_row {\n  color: #333333;\n  background-color: aliceblue;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ocwohzycsx .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_grand_summary_row {\n  color: #333333;\n  background-color: aliceblue;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ocwohzycsx .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#ocwohzycsx .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_footnotes {\n  color: #333333;\n  background-color: aliceblue;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#ocwohzycsx .gt_sourcenotes {\n  color: #333333;\n  background-color: aliceblue;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ocwohzycsx .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#ocwohzycsx .gt_left {\n  text-align: left;\n}\n\n#ocwohzycsx .gt_center {\n  text-align: center;\n}\n\n#ocwohzycsx .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#ocwohzycsx .gt_font_normal {\n  font-weight: normal;\n}\n\n#ocwohzycsx .gt_font_bold {\n  font-weight: bold;\n}\n\n#ocwohzycsx .gt_font_italic {\n  font-style: italic;\n}\n\n#ocwohzycsx .gt_super {\n  font-size: 65%;\n}\n\n#ocwohzycsx .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nInclusion criteria\n    Columns including or excluding these words are extracted from the Covid export\n    \n      inclusion_criterion\n    substantial pain\n    _50_\n      include\n    moderate\n      exclude\n    50_30\n      exclude\n    50_percent_50_percent\n      exclude\n    symptoms\n      exclude\n    impact\n      exclude\n    sleep\n    Sleep\n      include\n    Insomnia\n      include\n    qol\n    Quality of Life\n      include\n    qol\n      include\n    sf_36\n      include\n    eq_5d\n      include\n    physical function\n    Disability\n      include\n    Function\n      include\n    Physical component\n      include\n    Physical function\n      include\n    Sickness Impact Profile\n      include\n    Physical functioning\n      include\n    pgic\n    Global impression\n      include\n    Global judgement\n      include\n    Illness severity\n      include\n    Global Clinical Improvement\n      include\n    PGI-I\n      include\n    PGII-I\n      include\n    PGIC\n      include\n    CGI-S\n      include\n    Patient Global Assessment\n      include\n    Patient’s Global Evaluation\n      include\n    pain\n    Pain intensity\n      include\n    Pain severity\n      include\n    Pain unpleasantness\n      include\n    Somatisation\n      include\n    pain catastrophising\n      exclude\n    pain interference\n      exclude\n    50%\n      exclude\n    30%\n      exclude\n    mood\n    Mental health\n      include\n    Depression\n      include\n    Mood\n      include\n    Anxiety\n      include\n    Mental component\n      include\n    Psychosocial\n      include\n    Sadness\n      include\n    Well-being\n      include\n    moderate pain\n    _30_\n      include\n    substantial\n      exclude\n    50_30\n      include\n    50_percent_50_percent\n      exclude\n    symptoms\n      exclude\n    impact\n      exclude\n    adverse\n    Adverse drug reaction\n      include\n    Adverse events\n      include\n    Serious adverse events\n      include\n    \n\nprotocol notes\nbackground\nWe want to assess the comparative efficacy of antidepressants for adults with chronic pain.\ncondition\nchronic pain := > 3 months\nprimary pain := chronic pain as disease, e.g. lower back pain\nsecondary pian := pain with a specific cause, e.g., osteoarthritis\nassessed by self report\naffects 1/5 of adults in the world\naffects qol, mood, sleep, physical function\nintervention\ndifferent classes of treatment for chemical structure and mechanism of action\ncommon classes: TCA, SSRI, SNRI, MAOI\nantidepressants are sometimes used ‘off-license’ to treat chronic pain\nadverse events (e.g., headaches, weight loss) are associated with antidepressants\nhow\nantidepressants work by targeting neurotransmitters & receptors associated with mood & emotion\nprevent signal of pain from being absorbed\nperceived pain is reduced\nimportant\nno nma yet in pain + antidepressants\ncontradictory evidence\nno comparison of pain vs mood\nobjectives\nassess improvements in pain, mood, pgic, physical function, sleep, and qol by type, class, dose\nadverse events by type, class, dose\nrank efficacy in treating pain, negative affect, and adverse events\n\n\n\n",
      "last_modified": "2021-04-20T04:33:40+01:00"
    },
    {
      "path": "index.html",
      "title": "Cochrane intervention analysis",
      "description": "Key information about the analysis on the use of antidepressants to treat chronic pain\n",
      "author": [],
      "contents": "\n\n\n\n\n\n\n\n\n\nAs of Tuesday 20 April 2021, the analysis currently includes 162 out of an expected 178 studies.\n\n\n\nanalysis pipeline\n\n\n{\"x\":{\"nodes\":{\"name\":[\"obs_numeric\",\"network_binom\",\"outcomes\",\"outcomes_excluded_from_pipeline\",\"network_smd\",\"obs_measures\",\"obs_timepoints\",\"models\",\"model_smd\",\"obs_smd\",\"hpp_dat\",\"keywords\",\"data_update_date\",\"outcomes_of_interest\",\"obs_meta\",\"all_outcomes\",\"raw_hpp_dat\",\"raw_dat_path\",\"model_binom\",\"obs_wide_by_measures\",\"obs_postint\",\"pairwise_smd\",\"obs\",\"obs_binom\"],\"type\":[\"pattern\",\"pattern\",\"stem\",\"stem\",\"pattern\",\"pattern\",\"pattern\",\"stem\",\"pattern\",\"stem\",\"stem\",\"stem\",\"stem\",\"stem\",\"pattern\",\"stem\",\"stem\",\"stem\",\"pattern\",\"pattern\",\"pattern\",\"pattern\",\"pattern\",\"stem\"],\"status\":[\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\"],\"seconds\":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],\"bytes\":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],\"branches\":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],\"id\":[\"obs_numeric\",\"network_binom\",\"outcomes\",\"outcomes_excluded_from_pipeline\",\"network_smd\",\"obs_measures\",\"obs_timepoints\",\"models\",\"model_smd\",\"obs_smd\",\"hpp_dat\",\"keywords\",\"data_update_date\",\"outcomes_of_interest\",\"obs_meta\",\"all_outcomes\",\"raw_hpp_dat\",\"raw_dat_path\",\"model_binom\",\"obs_wide_by_measures\",\"obs_postint\",\"pairwise_smd\",\"obs\",\"obs_binom\"],\"label\":[\"obs_numeric\",\"network_binom\",\"outcomes\",\"outcomes_excluded_from_pipeline\",\"network_smd\",\"obs_measures\",\"obs_timepoints\",\"models\",\"model_smd\",\"obs_smd\",\"hpp_dat\",\"keywords\",\"data_update_date\",\"outcomes_of_interest\",\"obs_meta\",\"all_outcomes\",\"raw_hpp_dat\",\"raw_dat_path\",\"model_binom\",\"obs_wide_by_measures\",\"obs_postint\",\"pairwise_smd\",\"obs\",\"obs_binom\"],\"level\":[9,12,4,3,12,5,7,14,13,11,3,1,2,3,8,2,2,1,13,6,10,12,4,11],\"color\":[\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\"],\"shape\":[\"square\",\"square\",\"dot\",\"dot\",\"square\",\"square\",\"square\",\"dot\",\"square\",\"dot\",\"dot\",\"dot\",\"dot\",\"dot\",\"square\",\"dot\",\"dot\",\"dot\",\"square\",\"square\",\"square\",\"square\",\"square\",\"dot\"]},\"edges\":{\"from\":[\"obs_meta\",\"obs_binom\",\"outcomes_of_interest\",\"all_outcomes\",\"obs_smd\",\"obs\",\"obs_wide_by_measures\",\"model_binom\",\"model_smd\",\"network_smd\",\"obs_postint\",\"outcomes\",\"raw_hpp_dat\",\"raw_dat_path\",\"all_outcomes\",\"hpp_dat\",\"obs_timepoints\",\"keywords\",\"raw_dat_path\",\"network_binom\",\"obs_measures\",\"obs_numeric\",\"outcomes_of_interest\",\"obs_smd\",\"hpp_dat\",\"keywords\",\"outcomes_of_interest\",\"obs_postint\",\"outcomes\"],\"to\":[\"obs_numeric\",\"network_binom\",\"outcomes\",\"outcomes_excluded_from_pipeline\",\"network_smd\",\"obs_measures\",\"obs_timepoints\",\"models\",\"models\",\"model_smd\",\"obs_smd\",\"obs_smd\",\"hpp_dat\",\"data_update_date\",\"outcomes_of_interest\",\"obs_meta\",\"obs_meta\",\"all_outcomes\",\"raw_hpp_dat\",\"model_binom\",\"obs_wide_by_measures\",\"obs_postint\",\"obs_postint\",\"pairwise_smd\",\"obs\",\"obs\",\"obs\",\"obs_binom\",\"obs_binom\"],\"arrows\":[\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\"]},\"nodesToDataframe\":true,\"edgesToDataframe\":true,\"options\":{\"width\":\"100%\",\"height\":\"100%\",\"nodes\":{\"shape\":\"dot\",\"physics\":false},\"manipulation\":{\"enabled\":false},\"edges\":{\"smooth\":{\"type\":\"cubicBezier\",\"forceDirection\":\"horizontal\"}},\"physics\":{\"stabilization\":false},\"layout\":{\"hierarchical\":{\"enabled\":true,\"direction\":\"LR\"}}},\"groups\":null,\"width\":null,\"height\":null,\"idselection\":{\"enabled\":false,\"style\":\"width: 150px; height: 26px\",\"useLabels\":true,\"main\":\"Select by id\"},\"byselection\":{\"enabled\":false,\"style\":\"width: 150px; height: 26px\",\"multiple\":false,\"hideColor\":\"rgba(200,200,200,0.5)\",\"highlight\":false},\"main\":{\"text\":\"\",\"style\":\"font-family:Georgia, Times New Roman, Times, serif;font-weight:bold;font-size:20px;text-align:center;\"},\"submain\":null,\"footer\":null,\"background\":\"rgba(0, 0, 0, 0)\",\"highlight\":{\"enabled\":false,\"hoverNearest\":false,\"degree\":1,\"algorithm\":\"all\",\"hideColor\":\"rgba(200,200,200,0.5)\",\"labelOnly\":true},\"collapse\":{\"enabled\":true,\"fit\":false,\"resetHighlight\":true,\"clusterOptions\":null,\"keepCoord\":true,\"labelSuffix\":\"(cluster)\"},\"legend\":{\"width\":0.2,\"useGroups\":false,\"position\":\"right\",\"ncol\":1,\"stepX\":100,\"stepY\":100,\"zoom\":true,\"nodes\":{\"label\":[\"Pattern\",\"Stem\"],\"shape\":[\"square\",\"dot\"],\"color\":[\"#899DA4\",\"#899DA4\"]},\"nodesToDataframe\":true}},\"evals\":[],\"jsHooks\":[]}\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "last_modified": "2021-04-20T04:33:48+01:00"
    },
    {
      "path": "overview.html",
      "title": "overview",
      "description": "Summary information about all data for all outcomes.\n",
      "author": [],
      "date": "`r Sys.Date()`",
      "contents": "\n\nContents\noverview\nintervention class\nNumber of studies by chronic pain condition\nNumber of studies by class\nmulti-armed studies\nFrequency of comparisons\n\n\n\n\n\n\n\n\n\n\n\nAs of Tuesday 20 April 2021, the analysis currently includes 166 out of an expected 178 studies.\n\n\n\noverview\nintervention class\n\n\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#jygkxlyxyp .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #f0f0f0;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_heading {\n  background-color: #f0f0f0;\n  text-align: center;\n  border-bottom-color: #f0f0f0;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #f0f0f0;\n  border-bottom-width: 0;\n}\n\n#jygkxlyxyp .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #f0f0f0;\n  border-top-width: 0;\n}\n\n#jygkxlyxyp .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_col_heading {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#jygkxlyxyp .gt_column_spanner_outer {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#jygkxlyxyp .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#jygkxlyxyp .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#jygkxlyxyp .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#jygkxlyxyp .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#jygkxlyxyp .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#jygkxlyxyp .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#jygkxlyxyp .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#jygkxlyxyp .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#jygkxlyxyp .gt_stub {\n  color: #333333;\n  background-color: #f0f0f0;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#jygkxlyxyp .gt_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#jygkxlyxyp .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_grand_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#jygkxlyxyp .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#jygkxlyxyp .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_footnotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#jygkxlyxyp .gt_sourcenotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#jygkxlyxyp .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#jygkxlyxyp .gt_left {\n  text-align: left;\n}\n\n#jygkxlyxyp .gt_center {\n  text-align: center;\n}\n\n#jygkxlyxyp .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#jygkxlyxyp .gt_font_normal {\n  font-weight: normal;\n}\n\n#jygkxlyxyp .gt_font_bold {\n  font-weight: bold;\n}\n\n#jygkxlyxyp .gt_font_italic {\n  font-style: italic;\n}\n\n#jygkxlyxyp .gt_super {\n  font-size: 65%;\n}\n\n#jygkxlyxyp .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nintervention type\n      number of studies\n      number of antidepressants\n      antidepressants\n    SNRI\n      73\n      8\n      venlafaxine; milnacipran; duloxetine; desvenlafaxine; pregabalin; esreboxetine; cbt; education\n    TCA\n      65\n      23\n      amitriptyline; nortriptyline; amitriptyline + fluphenazine; amitriptyline + placebo; imipramine; dothiepin; desipramine; amitriptyline + pyschotherapy; amitriptyline + support; doxepin; morphine + nortriptyline; nortriptyline + cbt; nortriptyline + mgt; combination; epidural; physiotherapy + amitriptyline; physical + amitriptyline; amitriptyline + cbt; nortriptyline + morphine; desipramine + cbt; gabapentin; trimipramine; clomipramine\n    not an antidepressant\n      50\n      38\n      NA\n    SSRI\n      30\n      8\n      fluoxetine + placebo; paroxetine; citalopram; escitalopram; fluoxetine; zimelidine; sertraline; cst + sertraline\n    SARI\n      4\n      1\n      trazodone\n    NaSSA\n      3\n      1\n      mirtazapine\n    TeCA\n      2\n      2\n      maprotiline; mianserin\n    a4b2 NNR agonist\n      1\n      1\n      abt\n    Hormone\n      1\n      1\n      melatonin\n    NaRI\n      1\n      1\n      reboxetine\n    NDRI\n      1\n      1\n      bupropion\n    Reversible MAOI\n      1\n      1\n      pirlindole\n    Reversible MAOI. RIMA.\n      1\n      1\n      moclobemide\n    TCA + SSRI\n      1\n      1\n      amitriptyline + fluoxetine\n    TCA+hormone\n      1\n      1\n      melatonin\n    tetracyclic antidepressant (TeCA)\n      1\n      1\n      maprotiline\n    Tetracyclic antidepressant (TeCA)\n      1\n      1\n      mianserin\n    Tetracyclic antidepressants (TeCA)\n      1\n      1\n      maprotiline\n    Tetracylic antidepressant (TeCA)\n      1\n      1\n      maprotiline\n    \n\nNumber of studies by chronic pain condition\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#ngphayapux .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #f0f0f0;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#ngphayapux .gt_heading {\n  background-color: #f0f0f0;\n  text-align: center;\n  border-bottom-color: #f0f0f0;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ngphayapux .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #f0f0f0;\n  border-bottom-width: 0;\n}\n\n#ngphayapux .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #f0f0f0;\n  border-top-width: 0;\n}\n\n#ngphayapux .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ngphayapux .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ngphayapux .gt_col_heading {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#ngphayapux .gt_column_spanner_outer {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#ngphayapux .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#ngphayapux .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#ngphayapux .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#ngphayapux .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ngphayapux .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ngphayapux .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#ngphayapux .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#ngphayapux .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#ngphayapux .gt_stub {\n  color: #333333;\n  background-color: #f0f0f0;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#ngphayapux .gt_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ngphayapux .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#ngphayapux .gt_grand_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ngphayapux .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#ngphayapux .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#ngphayapux .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ngphayapux .gt_footnotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ngphayapux .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#ngphayapux .gt_sourcenotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ngphayapux .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#ngphayapux .gt_left {\n  text-align: left;\n}\n\n#ngphayapux .gt_center {\n  text-align: center;\n}\n\n#ngphayapux .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#ngphayapux .gt_font_normal {\n  font-weight: normal;\n}\n\n#ngphayapux .gt_font_bold {\n  font-weight: bold;\n}\n\n#ngphayapux .gt_font_italic {\n  font-style: italic;\n}\n\n#ngphayapux .gt_super {\n  font-size: 65%;\n}\n\n#ngphayapux .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nChronic pain condition\n      Number of studies\n      Number of interventions\n    Fibromyalgia\n      54\n      72\n    Chronic low back pain\n      8\n      15\n    Diabetic peripheral neuropathy\n      4\n      11\n    Painful diabetic neuropathy\n      4\n      11\n    Diabetic peripheral neuropathic pain\n      4\n      8\n    Knee osteoarthritis\n      4\n      6\n    Diabetic Peripheral Neuropathic Pain\n      3\n      7\n    Rheumatoid Arthritis\n      3\n      5\n    Chronic Low Back Pain\n      3\n      3\n    Non-cardiac chest pain\n      2\n      6\n    Painful polyneuropathy\n      2\n      6\n    Low back pain\n      2\n      5\n    Post-herpetic neuralgia\n      2\n      5\n    Postherpetic neuralgia\n      2\n      5\n    Burning Mouth Syndrome\n      2\n      4\n    Knee Osteoarthritis\n      2\n      3\n    “19 patients with painful diabetic polyneuropathy and 18 patients with painful nondiabetic polyneuropathy”\n      1\n      6\n    painful diabetic peripheral neuropathy (DPN).\n      1\n      5\n    Chronic neuropathic pain following treatment for breast cancer\n      1\n      4\n    Chronic Postherpetic Neuralgia\n      1\n      4\n    Chronic temporomandibular disorders\n      1\n      4\n    Chronic, intractable 'psychogenic' pain\n      1\n      4\n    Functional Bowel DIsorders\n      1\n      4\n    Low back pain/lumbar radiculopathy\n      1\n      4\n    Temporomandibular Joint Disorders (TMD)\n      1\n      4\n    Vulvodynia\n      1\n      4\n    Central post-stroke pain\n      1\n      3\n    Chronic pain syndromes: of the 59 randomised participants: 27 presented with low back pain, 16 with\nosteoarthritis, 8 with fibromyalgia, and 8 with rheumatoid arthritis\n      1\n      3\n    Chronic peripheral neuropathic pain\nConditions include: n(%)\nDiabetic peripheral neuropathy: 16 (31%)\nIdiopathic polyneuropathy: 15 (29%)\nPostherpetic neuralgia: 12 (23%)\nChemotherapy-induced peripheral neuropathy: 6 (12%)\nPosttraumatic neuropathy: 2 (4%)\nMyelin-associated glycoprotein neuropathy: 1 (2%)\n      1\n      3\n    Diabetic neuropathic pain\n      1\n      3\n    Diabetic polyneuropathy\n      1\n      3\n    Diabetic polyneuropathy and post-herpetic neuralgia\n      1\n      3\n    Hand osteoarthritis\n      1\n      3\n    Idiopathic pain syndrome, mainly: tension headache, burning mouth syndrome, abdominal pain and low back pain.       .     In brief, of the included 253 patients in the study byLoldrup et al. (1989) 114 had tension headache (age: 17–69 years, median 41.0 years; 64% females); 47 patients hadabdominal pain (age: 20–78 years, median 45.5 years; 70%females); 15 patients with low back pain (age: 26–68 years;median 40 years; 60% females); and 77 patients with burningmouth (age: 38–80 years; median 63 years; 92% females).\n      1\n      3\n    Irritable Bowel Syndrome, Diarrhea-predominant IBS was the most common\ncondition in each study group.\n      1\n      3\n    Neuropathic pain (post-herpetic neuralgia, diabetic polyneuropathy, traumatic plexus avulsion, peripheral nerve injury, failed back surgery syndrome, phantom pain, post-stroke pain)\n      1\n      3\n    Painful diabetic peripheral neuropathy\n      1\n      3\n    Severe IBS\n      1\n      3\n    Arm pain -  We included individuals with a range of clinical diagnoses involving the tendons, soft tissues and nerves of the arm, as well as those with non-specific arm symptoms related to movement (‘‘overuse strain syndrome”).\n      1\n      2\n    Atypical facial pain\n      1\n      2\n    Central neuropathic pain caused by lesion or dysfunction in the CNS.\n      1\n      2\n    Central pain in Multiple Sclerosis\n      1\n      2\n    Chemotherapy-Induced Painful Peripheral Neuropathy\n      1\n      2\n    Chronic cervical and/or lumbar spine pain\n      1\n      2\n    Chronic knee osteoarthritis\n      1\n      2\n    Chronic low back pain with a neuropathic component\n      1\n      2\n    Chronic neck pain\n      1\n      2\n    Chronic neuropathic low back pain\n      1\n      2\n    Chronic pain of various origins\n      1\n      2\n    chronic pain syndromes\nfrom deafferentation and with oncological pain\nwith deafferentation component . Of the 45 patients entered into the\nstudy, 27 were affected by pain caused by tumors\nand 18 by pain from other causes.\n      1\n      2\n    Chronic pain syndromes - 13 patients were regarded as having pain syndromes of predominantly organic origin while 27 of the patients had pain syndromes of predominantly psychogenic origin.\n      1\n      2\n    Chronic pelvic pain\n\n      1\n      2\n    Chronic phantom limb pain/residual limb pain after amputation\n      1\n      2\n    Diabetic Peripheral Neuropathic Pain (DPNP)\n      1\n      2\n    Diabetic Peripheral Neuropathy\n      1\n      2\n    Fibromyalgia with insomnia\n      1\n      2\n    Functional Chest Pain\n      1\n      2\n    Functional Gastrointestinal Disorder\n      1\n      2\n    Idiopathic pain syndrome (as defined by Williams and Spitzer, 1982). Most patients had more than one symptom and majority of patients had moderate to severe pain in the head region and/or chronic pain in neck, shoulders, arms and/or back.\n      1\n      2\n    Interstitial cystitis (IC)\n      1\n      2\n    Interstitial cystitis/painful bladder syndrome (IC/PBS)\n      1\n      2\n    Irritable bowel syndrome\n      1\n      2\n    Irritable Bowel Syndrome\n      1\n      2\n    Multiple functional somatic syndromes\n      1\n      2\n    Neuropathic pain associated with Multiple Sclerosis.\n      1\n      2\n    Osteoarthritis of the hip or knee\n      1\n      2\n    Osteoarthritis of the knee\n      1\n      2\n    Pain related to Parkinson's disease\n      1\n      2\n    Painful Diabetic Neuropathy\n      1\n      2\n    Painful diabetic peripheral polyneuropathy\n      1\n      2\n    Painful peripheral diabetic neuropathy\n      1\n      2\n    Persistent somatoform pain disorder\n      1\n      2\n    Polyneuropathy\n      1\n      2\n    Primary fibrositis, fibromyalgia\n      1\n      2\n    Rheumatoid  arthritis\n      1\n      2\n    Rheumatoid arthritis\n      1\n      2\n    Rheumatoid arthritis as ≥5 body pain sites\n      1\n      2\n    Somatoform symptoms and medically unexplained symptoms\n      1\n      2\n    Somatoform, DSM-IV-TR pain disorder\n      1\n      2\n    Spinal cord injury (SCI)\n      1\n      2\n    The majority of subjects had simple, nonspecific low back pain.\nSome subjects had multifocal pain resulting from associated fibromyalgia, but, in all cases, pain in the low back\nwas the predominant complaint.\n      1\n      2\n    \n\nNumber of studies by class\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#xlfrwjgsyj .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #f0f0f0;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_heading {\n  background-color: #f0f0f0;\n  text-align: center;\n  border-bottom-color: #f0f0f0;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #f0f0f0;\n  border-bottom-width: 0;\n}\n\n#xlfrwjgsyj .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #f0f0f0;\n  border-top-width: 0;\n}\n\n#xlfrwjgsyj .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_col_heading {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#xlfrwjgsyj .gt_column_spanner_outer {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#xlfrwjgsyj .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#xlfrwjgsyj .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#xlfrwjgsyj .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#xlfrwjgsyj .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#xlfrwjgsyj .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#xlfrwjgsyj .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#xlfrwjgsyj .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#xlfrwjgsyj .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#xlfrwjgsyj .gt_stub {\n  color: #333333;\n  background-color: #f0f0f0;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#xlfrwjgsyj .gt_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#xlfrwjgsyj .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_grand_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#xlfrwjgsyj .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#xlfrwjgsyj .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_footnotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#xlfrwjgsyj .gt_sourcenotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#xlfrwjgsyj .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#xlfrwjgsyj .gt_left {\n  text-align: left;\n}\n\n#xlfrwjgsyj .gt_center {\n  text-align: center;\n}\n\n#xlfrwjgsyj .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#xlfrwjgsyj .gt_font_normal {\n  font-weight: normal;\n}\n\n#xlfrwjgsyj .gt_font_bold {\n  font-weight: bold;\n}\n\n#xlfrwjgsyj .gt_font_italic {\n  font-style: italic;\n}\n\n#xlfrwjgsyj .gt_super {\n  font-size: 65%;\n}\n\n#xlfrwjgsyj .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nintervention\n      number of studies\n      number of dosages\n    Antidepressant\n    duloxetine\n      43\n      23\n    amitriptyline\n      35\n      24\n    milnacipran\n      17\n      10\n    paroxetine\n      9\n      8\n    venlafaxine\n      8\n      9\n    fluoxetine\n      7\n      3\n    nortriptyline\n      7\n      5\n    imipramine\n      6\n      5\n    citalopram\n      5\n      4\n    desipramine\n      5\n      4\n    maprotiline\n      4\n      5\n    escitalopram\n      3\n      3\n    mirtazapine\n      3\n      2\n    trazodone\n      3\n      3\n    amitriptyline + placebo\n      2\n      1\n    clomipramine\n      2\n      2\n    desvenlafaxine\n      2\n      8\n    dothiepin\n      2\n      2\n    doxepin\n      2\n      2\n    esreboxetine\n      2\n      3\n    fluoxetine + placebo\n      2\n      1\n    mianserin\n      2\n      2\n    sertraline\n      2\n      1\n    bupropion\n      1\n      1\n    moclobemide\n      1\n      1\n    pirlindole\n      1\n      1\n    reboxetine\n      1\n      1\n    trimipramine\n      1\n      1\n    zimelidine\n      1\n      1\n    Anticonvulsant\n    pregabalin\n      9\n      8\n    gabapentin\n      4\n      4\n    carbamazepine\n      3\n      3\n    lamotrigine\n      1\n      1\n    Active placebo\n    benzotropine\n      2\n      2\n    benztropine\n      1\n      1\n    diphenhydramine\n      1\n      1\n    Psychological therapy\n    cbt\n      2\n      1\n    psychotherapy\n      1\n      1\n    Neuronal nicotinic acetylcholine receptor agonist\n    abt\n      1\n      3\n    Analgesic\n    acetaminophen\n      1\n      1\n    Acupuncture\n    acupuncture\n      1\n      1\n    Exercise\n    aerobic\n      1\n      1\n    Antidepressant + Active placebo: Vitamin B2\n    amitriptyline\n      1\n      1\n    Antidepressant + NSAID\n    amitriptyline\n      1\n      1\n    Antidepressant and psychological therapy\n    amitriptyline + cbt\n      1\n      1\n    Combination of Antidepressant + Antidepressant\n    amitriptyline + fluoxetine\n      1\n      1\n    Antidepressant + Antipsychotic\n    amitriptyline + fluphenazine\n      1\n      1\n    Antidepressant + placebo\n    amitriptyline + placebo\n      1\n      1\n    Antidepressant + psychological therapy\n    amitriptyline + pyschotherapy\n      1\n      1\n    desipramine + cbt\n      1\n      1\n    nortriptyline + cbt\n      1\n      1\n    Antidepressant + clinician support\n    amitriptyline + support\n      1\n      1\n    Active placebo + psychological therapy\n    benztropine + cbt\n      1\n      1\n    placebo + cbt\n      1\n      1\n    Active placebo + disease management\n    benztropine + mgt\n      1\n      1\n    Behavioural (CBT) plus antidepressant medication\n    cbt\n      1\n      1\n    Behavioural (CBT) plus placebo (sugar pill) medication\n    cbt + placebo\n      1\n      1\n    Anticonvulsant + Antidepressant\n    combination\n      1\n      1\n    gabapentin\n      1\n      1\n    pregabalin\n      1\n      1\n    Medicinal plant\n    crocin\n      1\n      1\n    Psychological therapy + placebo\n    cst + placebo\n      1\n      1\n    Psychological therapy + antidepressant\n    cst + sertraline\n      1\n      1\n    Skeletal Muscle Relaxant\n    cyclobenzaprine\n      1\n      1\n    Antidepressant + placebo cream\n    desipramine\n      1\n      1\n    Antidepressant + topical  local anaesthetic\n    desipramine\n      1\n      1\n    Antidepressant + Ibuprofen 1800mg\n    dothiepin\n      1\n      1\n    Education\n    edu\n      1\n      1\n    Placebo (education) plus antidepressant medication\n    education\n      1\n      1\n    Epidural injection + antidepressant\n    epidural\n      1\n      1\n    Epidural injection + placebo\n    epidural\n      1\n      1\n    Antidepressant + Hormone\n    fluoxetine\n      1\n      2\n    Antidepressant + Placebo\n    fluoxetine + placebo\n      1\n      1\n    Antipsychotic\n    fluphenazine\n      1\n      1\n    Active Placebo\n    glycopyrrolate\n      1\n      1\n    Placebo tablet + topical  local anaesthetic\n    lidocaine\n      1\n      1\n    Benzodiazepine\n    lorazepam\n      1\n      1\n    Combination of hormone and antidepressant\n    melatonin\n      1\n      1\n    Hormone\n    melatonin\n      1\n      1\n    Hormone + Placebo\n    melatonin\n      1\n      1\n    Opioid\n    morphine\n      1\n      1\n    Painkiller\n    morphine\n      1\n      1\n    pregabalin\n      1\n      1\n    Combination opioid and antidepressant\n    morphine + nortriptyline\n      1\n      1\n    Synthetic cannabinoid\n    nabilone\n      1\n      1\n    Neurofeedback\n    neurofeedback\n      1\n      1\n    Antidepressant + disease management\n    nortriptyline + mgt\n      1\n      1\n    Combination painkiller and antidepressant\n    nortriptyline + morphine\n      1\n      1\n    Active comparator\n    panax\n      1\n      1\n    saffron\n      1\n      1\n    Cardiovascular fitness training\n    physical\n      1\n      1\n    Cardiovascular fitness training and amitriptyline\n    physical + amitriptyline\n      1\n      1\n    Physiotherapy and antidepressant\n    physiotherapy + amitriptyline\n      1\n      1\n    Placebo + cognitive behavioural therapy\n    placebo + cbt\n      1\n      1\n    Placebo\n    placebo + placebo\n      1\n      1\n    Placebo + psychological therapy\n    placebo + psychotherapy\n      1\n      1\n    Placebo + clinician support\n    placebo + support\n      1\n      1\n    Active placebo: Vitamin B2\n    riboflavin\n      1\n      1\n    Antidepressant + anticonvulsant\n    trazodone\n      1\n      1\n    Antidepressant + Anticonvulsant\n    trazodone\n      1\n      1\n    Usual care\n    usual\n      1\n      1\n    \n\nmulti-armed studies\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#pglzwsvszu .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #f0f0f0;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_heading {\n  background-color: #f0f0f0;\n  text-align: center;\n  border-bottom-color: #f0f0f0;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #f0f0f0;\n  border-bottom-width: 0;\n}\n\n#pglzwsvszu .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #f0f0f0;\n  border-top-width: 0;\n}\n\n#pglzwsvszu .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_col_heading {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#pglzwsvszu .gt_column_spanner_outer {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#pglzwsvszu .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#pglzwsvszu .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#pglzwsvszu .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#pglzwsvszu .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#pglzwsvszu .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#pglzwsvszu .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#pglzwsvszu .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#pglzwsvszu .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#pglzwsvszu .gt_stub {\n  color: #333333;\n  background-color: #f0f0f0;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#pglzwsvszu .gt_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#pglzwsvszu .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_grand_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#pglzwsvszu .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#pglzwsvszu .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_footnotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#pglzwsvszu .gt_sourcenotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#pglzwsvszu .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#pglzwsvszu .gt_left {\n  text-align: left;\n}\n\n#pglzwsvszu .gt_center {\n  text-align: center;\n}\n\n#pglzwsvszu .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#pglzwsvszu .gt_font_normal {\n  font-weight: normal;\n}\n\n#pglzwsvszu .gt_font_bold {\n  font-weight: bold;\n}\n\n#pglzwsvszu .gt_font_italic {\n  font-style: italic;\n}\n\n#pglzwsvszu .gt_super {\n  font-size: 65%;\n}\n\n#pglzwsvszu .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nstudy\n      number of interventions\n      interventions\n    Functional Bowel Disorder symptoms\n    Drossman 2003\n      4\n      placebo; desipramine; cbt; edu\n    Pain\n    Goldenberg 1986\n      4\n      amitriptyline; placebo; amitriptyline + placebo; placebo + placebo\n    Gould 2020\n      4\n      placebo; desipramine; placebo + cbt; desipramine + cbt\n    Graff-Radford 2000\n      4\n      amitriptyline; amitriptyline + fluphenazine; fluphenazine; glycopyrrolate\n    Holbech 2015\n      4\n      placebo; pregabalin; imipramine; combination\n    Khoromi 2007\n      4\n      benzotropine; morphine; nortriptyline; morphine + nortriptyline\n    Nct 2003\n      4\n      benztropine + cbt; nortriptyline + cbt; benztropine + mgt; nortriptyline + mgt\n    Pilowsky 1990\n      4\n      amitriptyline + pyschotherapy; amitriptyline + support; placebo + psychotherapy; placebo + support\n    Atkinson 1999\n      3\n      maprotiline; paroxetine; diphenhydramine\n    Enteshari-Moghaddam 2019\n      3\n      acetaminophen; duloxetine; gabapentin\n    Foster 2010 | 1\n      3\n      placebo; lidocaine; desipramine; desipramine\n    Gilron 2015\n      3\n      morphine; nortriptyline; nortriptyline + morphine\n    Gilron 2016\n      3\n      placebo; pregabalin; duloxetine; pregabalin\n    Hannonen 1998\n      3\n      moclobemide; amitriptyline; placebo\n    Leijon 1989\n      3\n      placebo; amitriptyline; carbamazepine\n    Max 1988\n      3\n      placebo; amitriptyline; lorazepam\n    Rani 1996\n      3\n      placebo; fluoxetine; amitriptyline\n    Razazian 2014\n      3\n      carbamazepine; pregabalin; venlafaxine\n    Rowbotham 2005\n      3\n      desipramine; amitriptyline; fluoxetine\n    Rowbotham 2012\n      3\n      placebo; duloxetine; abt; abt; abt\n    Sencan 2004\n      3\n      aerobic; paroxetine; placebo\n    Sindrup 1990\n      3\n      placebo; paroxetine; imipramine\n    Sindrup 2003\n      3\n      placebo; venlafaxine; imipramine\n    Sofat 2016\n      3\n      placebo; pregabalin; duloxetine\n    Spinhoven 2010\n      3\n      placebo; paroxetine; cbt\n    Vrethem 1997\n      3\n      amitriptyline; amitriptyline; maprotiline; maprotiline; placebo; placebo\n    Pain, depression, quality of life and sleep\n    Calderon 2011\n      4\n      placebo; placebo + cbt; amitriptyline; amitriptyline + cbt\n    Pain, mood/anxiety and physical disability\n    Keefe 2011\n      4\n      placebo; sertraline; cst + placebo; cst + sertraline\n    Pain, tender points\n    Goldenberg 1996\n      4\n      placebo; amitriptyline + placebo; fluoxetine + placebo; amitriptyline + fluoxetine\n    Fibromyalgia symptoms\n    Braz 2013\n      3\n      placebo; amitriptyline; panax\n    Heymann 2001\n      3\n      amitriptyline; nortriptyline; placebo\n    Hussain 2011\n      3\n      melatonin; fluoxetine + placebo; fluoxetine; fluoxetine\n    IBS symptoms\n    Talley 2008\n      3\n      placebo; imipramine; citalopram\n    Mood and pain\n    Loldrup 1989\n      3\n      placebo; clomipramine; mianserin\n    Pain (pressure point)\n    Isomeri 1993\n      3\n      physiotherapy + amitriptyline; physical; physical + amitriptyline\n    Pain and fibromyalgia symptoms\n    Carette 1994\n      3\n      placebo; amitriptyline; cyclobenzaprine\n    Pain and HRQoL\n    Creed 2003\n      3\n      psychotherapy; paroxetine; usual\n    Pain and physical function\n    Ang 2013\n      3\n      cbt + placebo; cbt; education\n    Pain intensity\n    Nct 2006\n      3\n      pregabalin; amitriptyline; duloxetine\n    \n\nFrequency of comparisons\n\n\n\n",
      "last_modified": "2021-04-20T04:34:07+01:00"
    },
    {
      "path": "template-outcome-analysis-generator.html",
      "title": "analysis",
      "description": "Efficacy of antidepressants for adults with chronic pain\n",
      "author": [],
      "date": "last updated `r Sys.Date()`",
      "contents": "\n\nContents\nnetwork and model\narm-based likelihood\ncontrast-based likelihood\n\nmodel results\npairwise analyses\nwhy do pairwise\npairwise meta-analysis\npairwise model\n\ninput: design matrix\noutput\nstructuring nma data for metafor\nconcise summary\nlong-form supplementary\n\n\n\n\n\n\n\n\n\n\n\nnetwork and model\nNetwork meta-analysis provides a means of aggregating and comparing the results of all studies examining the effect of antidepressants on pain.\nWe now define the parameters of the model for the pain outcome, using White et al.’s notation.\nLet \\(i = 1, \\dots, n\\) denote the study, and \\(k = 1, \\dots, K\\) denote the treatment.\nLet \\(R_i\\) be the set of treatments in study \\(i\\), which we call the study design.\nLet \\(\\theta_{ik}^a\\) be the parameter of interest in arm \\(k\\) of study \\(i\\) (White et al. 2019).\nLet \\(y_{ik}^a\\) denote the observed effect for arm \\(k\\) of study \\(i\\).\narm-based likelihood\nArm-based likelihood is\n\n\n\ncontrast-based likelihood\nmodel results\n\n\n\n\n\n\npairwise analyses\nIndividual analyses for each treatment, compared with placebo.\n\nadapt notation to our problem\nwhy do pairwise\npairwise meta-analysis\nWe want to fit a pairwise meta-analysis for each treatment, with concise summaries, as well as in-depth supplementary material. We split the analysis into two components, as the number of interventions per outcome is considerable, see below Table, in some cases, according to recommendations in Section 11.6.4 of the Handbook (Higgins et al. 2019).\n\n\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#ajrmgcfhdk .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#ajrmgcfhdk .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#ajrmgcfhdk .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#ajrmgcfhdk .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#ajrmgcfhdk .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#ajrmgcfhdk .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#ajrmgcfhdk .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#ajrmgcfhdk .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ajrmgcfhdk .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ajrmgcfhdk .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#ajrmgcfhdk .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#ajrmgcfhdk .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#ajrmgcfhdk .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#ajrmgcfhdk .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ajrmgcfhdk .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ajrmgcfhdk .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#ajrmgcfhdk .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#ajrmgcfhdk .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ajrmgcfhdk .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#ajrmgcfhdk .gt_left {\n  text-align: left;\n}\n\n#ajrmgcfhdk .gt_center {\n  text-align: center;\n}\n\n#ajrmgcfhdk .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#ajrmgcfhdk .gt_font_normal {\n  font-weight: normal;\n}\n\n#ajrmgcfhdk .gt_font_bold {\n  font-weight: bold;\n}\n\n#ajrmgcfhdk .gt_font_italic {\n  font-style: italic;\n}\n\n#ajrmgcfhdk .gt_super {\n  font-size: 65%;\n}\n\n#ajrmgcfhdk .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nNumber of studies and interventions, by outcome\n    Interventions include placebo, as sometimes there are more than one type of placebo\n    Outcome\n      Number of studies\n      Number of interventions\n    substantial pain\n      4\n      5\n    pain\n      44\n      28\n    mood\n      61\n      42\n    \n\npairwise model\nTo avoid confusion, we need to state the pairwise models being fun using the same notation as we use for the network meta-analysis models.\nHere we consider a subset of data for \\(j\\), that is for only one outcome, \\(j'\\), so that we expect the same as above except we fix the index, so that \\(y^a_{j = j'|ki}\\).\n\\[\nd_i \\sim N(\\delta_i, \\sigma^2)\\\\\n\\delta_{i} \\sim N(\\delta, \\tau^2)\n\\] Given the data, what description of the data is most plausible, if we define the components of the data as follows? We assume a random-effects structure, which is to say, we can approximate, with a measurable degree of plausibility, the expected value of a standardised mean difference \\(d_i\\) of an outcome \\(j'\\) of interest for a study \\(i\\) and antidepressant treatment \\(k\\), as compared with placebo. We assume there is variability introduced by the study design \\(\\tau^2\\), as well as sampling error \\(\\sigma^2\\).\n\n\n\n\n\n\ninput: design matrix\n\nA random effects NMA with a normal likelihood (identity link).\nInference for Stan model: normal.\n4 chains, each with iter=2000; warmup=1000; thin=1; \npost-warmup draws per chain=1000, total post-warmup draws=4000.\n\n                        mean se_mean    sd    2.5%     25%     50%\nd[abt]                 -0.15    0.03  0.69   -1.54   -0.61   -0.15\nd[acetaminophen]       28.11    0.05  2.33   23.61   26.55   28.06\nd[amitriptyline]       -0.77    0.02  0.51   -1.75   -1.11   -0.77\nd[benzotropine]         7.42    0.06  2.87    1.75    5.49    7.38\nd[cbt]                 -0.16    0.20  5.88  -11.51   -4.22   -0.15\nd[cbt + placebo]        0.31    0.20  5.84  -11.16   -3.61    0.28\nd[citalopram]           0.18    0.20  7.04  -13.59   -4.53    0.18\nd[cst + placebo]       -1.27    0.07  2.86   -6.75   -3.20   -1.26\nd[cst + sertraline]    -2.88    0.07  2.66   -8.06   -4.73   -2.94\nd[cyclobenzaprine]     -0.61    0.03  0.99   -2.58   -1.27   -0.62\nd[desipramine]         -1.09    0.04  1.68   -4.33   -2.25   -1.11\nd[desipramine + cbt]    0.06    0.04  1.64   -3.21   -1.02    0.09\nd[desvenlafaxine]      -0.74    0.04  0.86   -2.42   -1.31   -0.75\nd[diphenhydramine]      0.27    0.21  5.97  -11.48   -3.84    0.35\nd[duloxetine]          -0.59    0.03  0.23   -1.05   -0.75   -0.60\nd[education]            1.01    0.20  5.86  -10.30   -2.97    0.97\nd[fluoxetine]          -0.63    0.03  0.99   -2.60   -1.28   -0.60\nd[gabapentin]          -2.90    0.05  1.96   -6.70   -4.20   -2.95\nd[maprotiline]         -0.60    0.20  5.97  -12.38   -4.71   -0.58\nd[melatonin]           -1.67    0.12  5.38  -12.13   -5.21   -1.72\nd[milnacipran]         -0.99    0.02  0.65   -2.27   -1.44   -0.99\nd[mirtazapine]         -0.42    0.02  1.07   -2.47   -1.13   -0.41\nd[nortriptyline]        2.00    0.02  1.04   -0.05    1.31    2.01\nd[paroxetine]           0.78    0.20  5.93  -11.18   -3.24    0.86\nd[placebo + cbt]       -1.03    0.04  1.67   -4.29   -2.15   -1.01\nd[reboxetine]           0.52    0.20  7.04  -13.00   -4.20    0.48\nd[sertraline]          -6.20    0.07  2.47  -11.12   -7.84   -6.19\nlp__                 -670.03    0.42 10.71 -691.75 -676.97 -669.84\ntau                     1.08    0.01  0.12    0.88    1.00    1.08\n                         75%   97.5% n_eff Rhat\nd[abt]                  0.32    1.18   750 1.01\nd[acetaminophen]       29.68   32.67  2405 1.00\nd[amitriptyline]       -0.42    0.21   781 1.01\nd[benzotropine]         9.40   13.19  2715 1.00\nd[cbt]                  3.78   11.51   859 1.00\nd[cbt + placebo]        4.15   11.90   869 1.00\nd[citalopram]           4.86   14.23  1245 1.00\nd[cst + placebo]        0.64    4.41  1533 1.00\nd[cst + sertraline]    -1.08    2.29  1385 1.00\nd[cyclobenzaprine]      0.06    1.27  1228 1.00\nd[desipramine]          0.03    2.22  1527 1.00\nd[desipramine + cbt]    1.16    3.29  1561 1.00\nd[desvenlafaxine]      -0.19    1.03   607 1.00\nd[diphenhydramine]      4.39   11.57   842 1.00\nd[duloxetine]          -0.43   -0.13    63 1.09\nd[education]            4.95   12.47   845 1.00\nd[fluoxetine]           0.04    1.29  1493 1.00\nd[gabapentin]          -1.59    0.90  1718 1.00\nd[maprotiline]          3.49   11.03   884 1.00\nd[melatonin]            1.89    9.26  1944 1.00\nd[milnacipran]         -0.55    0.29   917 1.01\nd[mirtazapine]          0.30    1.63  1908 1.00\nd[nortriptyline]        2.70    4.03  1857 1.00\nd[paroxetine]           4.76   12.23   856 1.00\nd[placebo + cbt]        0.07    2.29  1528 1.00\nd[reboxetine]           5.38   14.68  1242 1.00\nd[sertraline]          -4.51   -1.46  1310 1.00\nlp__                 -662.61 -649.98   643 1.01\ntau                     1.16    1.33   350 1.01\n\nSamples were drawn using NUTS(diag_e) at Tue Apr 20 02:58:07 2021.\nFor each parameter, n_eff is a crude measure of effective sample size,\nand Rhat is the potential scale reduction factor on split chains (at \nconvergence, Rhat=1).\n\noutput\n\nA random effects NMA with a normal likelihood (identity link).\nInference for Stan model: normal.\n4 chains, each with iter=2000; warmup=1000; thin=1; \npost-warmup draws per chain=1000, total post-warmup draws=4000.\n\n                        mean se_mean    sd    2.5%     25%     50%\nd[abt]                 -0.15    0.03  0.69   -1.54   -0.61   -0.15\nd[acetaminophen]       28.11    0.05  2.33   23.61   26.55   28.06\nd[amitriptyline]       -0.77    0.02  0.51   -1.75   -1.11   -0.77\nd[benzotropine]         7.42    0.06  2.87    1.75    5.49    7.38\nd[cbt]                 -0.16    0.20  5.88  -11.51   -4.22   -0.15\nd[cbt + placebo]        0.31    0.20  5.84  -11.16   -3.61    0.28\nd[citalopram]           0.18    0.20  7.04  -13.59   -4.53    0.18\nd[cst + placebo]       -1.27    0.07  2.86   -6.75   -3.20   -1.26\nd[cst + sertraline]    -2.88    0.07  2.66   -8.06   -4.73   -2.94\nd[cyclobenzaprine]     -0.61    0.03  0.99   -2.58   -1.27   -0.62\nd[desipramine]         -1.09    0.04  1.68   -4.33   -2.25   -1.11\nd[desipramine + cbt]    0.06    0.04  1.64   -3.21   -1.02    0.09\nd[desvenlafaxine]      -0.74    0.04  0.86   -2.42   -1.31   -0.75\nd[diphenhydramine]      0.27    0.21  5.97  -11.48   -3.84    0.35\nd[duloxetine]          -0.59    0.03  0.23   -1.05   -0.75   -0.60\nd[education]            1.01    0.20  5.86  -10.30   -2.97    0.97\nd[fluoxetine]          -0.63    0.03  0.99   -2.60   -1.28   -0.60\nd[gabapentin]          -2.90    0.05  1.96   -6.70   -4.20   -2.95\nd[maprotiline]         -0.60    0.20  5.97  -12.38   -4.71   -0.58\nd[melatonin]           -1.67    0.12  5.38  -12.13   -5.21   -1.72\nd[milnacipran]         -0.99    0.02  0.65   -2.27   -1.44   -0.99\nd[mirtazapine]         -0.42    0.02  1.07   -2.47   -1.13   -0.41\nd[nortriptyline]        2.00    0.02  1.04   -0.05    1.31    2.01\nd[paroxetine]           0.78    0.20  5.93  -11.18   -3.24    0.86\nd[placebo + cbt]       -1.03    0.04  1.67   -4.29   -2.15   -1.01\nd[reboxetine]           0.52    0.20  7.04  -13.00   -4.20    0.48\nd[sertraline]          -6.20    0.07  2.47  -11.12   -7.84   -6.19\nlp__                 -670.03    0.42 10.71 -691.75 -676.97 -669.84\ntau                     1.08    0.01  0.12    0.88    1.00    1.08\n                         75%   97.5% n_eff Rhat\nd[abt]                  0.32    1.18   750 1.01\nd[acetaminophen]       29.68   32.67  2405 1.00\nd[amitriptyline]       -0.42    0.21   781 1.01\nd[benzotropine]         9.40   13.19  2715 1.00\nd[cbt]                  3.78   11.51   859 1.00\nd[cbt + placebo]        4.15   11.90   869 1.00\nd[citalopram]           4.86   14.23  1245 1.00\nd[cst + placebo]        0.64    4.41  1533 1.00\nd[cst + sertraline]    -1.08    2.29  1385 1.00\nd[cyclobenzaprine]      0.06    1.27  1228 1.00\nd[desipramine]          0.03    2.22  1527 1.00\nd[desipramine + cbt]    1.16    3.29  1561 1.00\nd[desvenlafaxine]      -0.19    1.03   607 1.00\nd[diphenhydramine]      4.39   11.57   842 1.00\nd[duloxetine]          -0.43   -0.13    63 1.09\nd[education]            4.95   12.47   845 1.00\nd[fluoxetine]           0.04    1.29  1493 1.00\nd[gabapentin]          -1.59    0.90  1718 1.00\nd[maprotiline]          3.49   11.03   884 1.00\nd[melatonin]            1.89    9.26  1944 1.00\nd[milnacipran]         -0.55    0.29   917 1.01\nd[mirtazapine]          0.30    1.63  1908 1.00\nd[nortriptyline]        2.70    4.03  1857 1.00\nd[paroxetine]           4.76   12.23   856 1.00\nd[placebo + cbt]        0.07    2.29  1528 1.00\nd[reboxetine]           5.38   14.68  1242 1.00\nd[sertraline]          -4.51   -1.46  1310 1.00\nlp__                 -662.61 -649.98   643 1.01\ntau                     1.16    1.33   350 1.01\n\nSamples were drawn using NUTS(diag_e) at Tue Apr 20 02:58:07 2021.\nFor each parameter, n_eff is a crude measure of effective sample size,\nand Rhat is the potential scale reduction factor on split chains (at \nconvergence, Rhat=1).\n\nstructuring nma data for metafor\n\n\n\n\n\n\nconcise summary\nlong-form supplementary\n\n\n\nHiggins, Julian PT, James Thomas, Jacqueline Chandler, Miranda Cumpston, Tianjing Li, Matthew J Page, and Vivian A Welch. 2019. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons.\n\n\nWhite, Ian R., Rebecca M. Turner, Amalia Karahalios, and Georgia Salanti. 2019. “A Comparison of Arm-Based and Contrast-Based Models for Network Meta-Analysis.” Statistics in Medicine 38 (27): 5197–5213. https://doi.org/https://doi.org/10.1002/sim.8360.\n\n\n\n\n",
      "last_modified": "2021-04-20T04:34:39+01:00"
    }
  ],
  "collections": []
}
